Updates are available Correction dated 2025-08-21
Click to view Correction: https://doi.org/10.1038/s41419-025-07910-8
-
Authors
Qi, Da
Lu, Yan
Qu, Huinan
Dong, Yuan
Jin, Qiu
Sun, Minghao
Quan, Chengshi https://orcid.org/0000-0001-9307-5279
-
Funding
Funding for this research was provided by:
National Natural Science Foundation of China
Science and Technology Development Projects of Jilin Province
Science and Technology Development Projects of Jilin Provinc
- License Information
-
More Information
Article History
Received: 5 August 2024
Revised: 6 January 2025
Accepted: 11 February 2025
First Online: 21 February 2025
Change Date: 21 August 2025
Change Type: Update
Change Details: The original online version of this article was revised: The supplementary file has been updated. In Fig. S3 B, the DCFH-DA staining image of RSL3-treated MCF-7 cells were pasted into the MDA-MB-231 cell group. In Fig. S3 C, we mistakenly pasted the C11 staining image of MCF-7 cells without ferroptosis inhibitor into the MDA-MB-231 cell group treated with sorafenib group. We have revised the two errors and shown the correction images in the corrected file. The statistical analysis and conclusion of the article are based on the correct original figures. The authors would like to assure readers that the corrected figures do not alter the interpretations or validity of the research.
Change Date: 21 August 2025
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41419-025-07910-8
Competing interests
: The authors declare no competing interests.
: The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Experimental Animal Ethical Committee of Jilin University (protocol code 2021.237 and 2022.72), the Ethics Committee of Shanghai Outdo Biotech CO and Hunan Aifang Biological (protocol code YB M-05-02).
